Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the Baseline visit~* Participant must have at least 3 distinct anatomical regions involved with inflammatory (also termed 'active') HS lesions; plus~  * either one axilla or one inguinal region (limited to the inguino-crural fold and adjacent areas) that requires excisional surgery, and~ * with at least one of the other affected HS regions (e.g., contralateral inguinal region, buttocks, inframammary region) rated as Hurley Stage II or III~* Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit within the HS non-surgical sites~* The HS surgical site must contain at least one active HS lesion~* The HS surgical site must require excisional surgery and is large enough to require healing by secondary intention as assessed by the designated surgeon~Exclusion Criteria:~* Participant has a draining fistula count of greater than 20 at the Baseline visit~* Participant requires surgery at any anatomical site other than an unilateral axilla or inguinal region site~* Participant requires surgical management prior to Week 13~* Participant requires, based on the designated surgeon's assessment, excisional surgery with primary closure as the method of closure being most beneficial for the participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week
- Adalimumab (Type: ACTIVE_COMPARATOR): Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week

Based on this trial design, predict the completion outcome and termination type (if applicable).